Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Result of AGM

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091102:RnsB7679B
                                                                                                                       .
RNS Number : 7679B  
  
ABCAM Plc  
  
02 November 2009  
  
 
  For immediate release   2 November2009  
  
  
ABCAM PLC  
  
("Abcam" or "the Company")  
  
Result of AGM and Board Update  
  
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets 
antibodies via its own online catalogue, announces that at its AGM held earlier 
today all resolutions put to the meeting were duly passed.  
  
As planned, Mike Redmond has now taken over as Chairman of the Company following 
David Cleevely's retirement from the Board at the AGM.   
  
Commenting on the handover, Mr Redmond, Abcam's Chairman, said:  
  
"On behalf of the Board I would like to thank David for the major contribution 
he has made to the establishment and development of Abcam as a world-leading 
company in its field. This is an exciting time to be at Abcam and I am very much 
looking forward to working with the team as we continue to take the Company 
forward."  
  
For further information please contact:   
  
Abcam                                       + 44 (0) 1223 696000   
  
Jonathan Milner, Chief Executive Officer   
  
Jeff Iliffe, Chief Financial Officer   
  
www.abcam.com   
  
Numis Securities                          + 44 (0) 20 7260 1000   
  
Michael Meade / Nick Westlake - Nominated Adviser  
  
James Black - Corporate Broking  
  
Buchanan Communications         + 44 (0) 20 7466 5000   
  
Mark Court / Stasa Filiplic  
  
Notes for editors  
  
About Abcam plc  
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its four operating companies.   
  
About antibodies  
  
Antibodies are proteins produced by white blood cells in response to the 
introduction of a foreign body known as an antigen. Antibodies, which have a 
wide variety of uses in research, diagnostics and therapeutics, are used by 
bioscientists in research into disease and into the human genome, where they are 
used to mark and identify specific cells and other living matter. The number of 
human antibodies of use in research is potentially greater than one million.   
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RAGCKBKBDBDDQDK  
  

---

back to RNS news